Landmark TrialRCTRandomized Controlled Trial
Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents
New England Journal of Medicine2014IF: 25.4
Laura Mauri, Larry S. Dean, Robert W. Yeh, Priscilla Driscoll-Shempp, Donald E. Cutlip, Philippe Gabríel Steg, Sharon‐Lise T. Normand, Eugene Braunwald, Stephen D. Wiviott, David J. Cohen, David R. Holmes, Mitchell W. Krucoff, James Hermiller, Harold L. Dauerman, Daniel I. Simon, David E. Kandzari, Kirk N. Garratt, David P. Lee, Thomas Pow, Peter Ver Lee, Michael J. Rinaldi, Joseph M. Massaro
Abstract
Dual antiplatelet therapy beyond 1 year after placement of a drug-eluting stent, as compared with aspirin therapy alone, significantly reduced the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events but was associated with an increased risk of bleeding. (Funded by a consortium of eight device and drug manufacturers and others; DAPT ClinicalTrials.gov number, NCT00977938.).